Haematology International Journal

MEDWIN PUBLISHERS ISSN: 2578-501X

Committed to Create Value for Researchers

Comprehensive Insights into Eosinophil Interactions in Sickle Cell

Anemia Severity

Obeagu EI*
Review Article
Department of Medical Laboratory Science, Kampala International University, Uganda Volume 8 Issue 1
Received Date: December 26, 2023
*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Published Date: January 09, 2024
Science, Kampala International University, Kampala, Uganda, Tel: +2348037369912; Email: DOI: 10.23880/hij-16000223
emmanuelobeagu@yahoo.com

Abstract

Sickle Cell Anemia (SCA) is a prevalent inherited blood disorder characterized by abnormal hemoglobin leading to erythrocyte
deformation and consequential vaso-occlusive events. While the primary focus has traditionally centered on the role of red
blood cells in SCA pathophysiology, recent investigations have unveiled the intricate involvement of eosinophils in modulating
disease severity. Eosinophils, classically recognized for their role in parasitic infections and allergic responses, have emerged
as significant contributors to the inflammatory milieu and vascular dysfunction observed in SCA. This paper aims to provide
an extensive understanding of the multifaceted interactions between eosinophils and the pathogenesis of sickle cell anemia,
emphasizing their impact on disease severity. Insights into eosinophil biology, including their cytokine release profile, granule
protein activity, and endothelial interactions, underscore their dual role in both propagating and modulating inflammation in
the context of SCA. The complex interplay between eosinophils and the inflammatory microenvironment in SCA dictates disease
severity, warranting a deeper understanding of these interactions for the development of targeted therapeutic strategies. In
conclusion, this comprehensive review consolidates current knowledge regarding eosinophil involvement in sickle cell anemia
severity, emphasizing the necessity for further investigations into specific eosinophilic mechanisms. A deeper comprehension
of eosinophilic contributions to SCA pathophysiology presents a pathway toward novel therapeutic modalities, ultimately
enhancing the management and prognosis of individuals afflicted with this challenging hematologic disorder.

Keywords: Sickle Cell Anemia; Eosinophils; Disease Severity; Inflammation; Immune Modulation; Vascular Dysfunction;
Therapeutic Targets

Abbreviations: SCA: Sickle Cell Anemia; ECP: Eosinophil
Cationic Protein; MBP: Major Basic Protein; IL: Interleukins.
Introduction
Sickle Cell Anemia (SCA) stands as a paradigmatic
hemoglobinopathy characterized by a point mutation in
the beta-globin gene, resulting in the synthesis of abnormal
hemoglobin HbS. This structural alteration triggers the
polymerization of hemoglobin molecules under hypoxic
conditions, prompting red blood cells to assume a sickle
shape. This hallmark feature underlies the pathophysiology
of SCA, manifesting in chronic hemolytic anemia, vaso-
occlusive crises, and end-organ damage, significantly
impacting patients’ quality of life [1-8]. Traditionally, the
focus of research and therapeutic strategies in SCA has

Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity Haematol Int J
 2
primarily revolved around understanding the erythrocyte-
centric aspects of the disease. However, recent scientific
inquiries have unveiled an intricate interplay between the
immune system and the progression of SCA, particularly
highlighting the contributions of eosinophils in influencing
disease severity.
Eosinophil’s, a specialized subset of granulocytes
classically associated with allergic responses and defense
against parasitic infections, have surfaced as pivotal mediators
in the multifaceted landscape of sickle cell anemia [9]. While
initially overshadowed by the dominance of red blood cell
aberrations, eosinophils have garnered attention due to
their involvement in modulating inflammatory responses,
immune dysregulation, and endothelial dysfunction, thereby
significantly impacting the clinical course of SCA [10].
This paper aims to delve into the burgeoning field of
eosinophil research within the context of sickle cell anemia,
elucidating the multifarious roles played by eosinophils
in shaping disease severity. By exploring the intricate
interactions between eosinophils and various pathological
mechanisms underlying SCA, this review endeavors to
provide a comprehensive understanding of how eosinophils
contribute to the intricate tapestry of SCA pathophysiology.
Overall, this paper amalgamates existing knowledge and
recent research findings to shed light on the emerging
significance of eosinophils in influencing the clinical course
of sickle cell anemia. By elucidating the nuanced interactions
between eosinophils and SCA pathogenesis, this review aims
to underscore the imperative need for further investigations
to unlock novel therapeutic opportunities and enhance
patient care in the realm of sickle cell disease.
Eosinophils in SCA
Sickle Cell Anemia (SCA), a complex genetic disorder
characterized by the presence of abnormal hemoglobin,
primarily affects red blood cells, leading to their characteristic
sickle-shaped appearance. While erythrocyte abnormalities
have been the central focus in understanding SCA
pathophysiology, recent investigations have shed light on the
intricate involvement of eosinophils, a subset of white blood
cells, in contributing to the disease’s clinical manifestations
and severity [11-17]. Studies have consistently reported
elevated eosinophil counts in individuals with SCA [18,19].
This heightened presence of eosinophils suggests their
active participation in the disease process. However, the
specific mechanisms governing their recruitment and
activation within the context of SCA remain areas of active
research. Eosinophils are known for their ability to secrete
an array of inflammatory mediators and cytokines, including
leukotrienes, interleukins (IL-4, IL-13), and granule proteins
(major basic protein - MBP-1, eosinophil cationic protein
Obeagu EI. Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity.
Haematol Int J 2024, 8(1): 00223.
Haematology International Journal
- ECP). These molecules play pivotal roles in promoting
inflammation and tissue damage, potentially exacerbating
the pathophysiology of SCA [20].
The interaction between eosinophils and immune
cells within the inflammatory microenvironment of SCA
contributes to altered immune responses. Eosinophils
possess both pro-inflammatory and anti-inflammatory
properties, participating in the modulation of T-cell
responses and impacting the overall immune landscape
in SCA [21,22]. Eosinophils are implicated in inducing
endothelial dysfunction by promoting oxidative stress
and expression of adhesion molecules. In the context of
SCA, these interactions might exacerbate vaso-occlusive
events, thus contributing to tissue ischemia and subsequent
organ damage [23]. Eosinophils have been associated
with promoting thrombotic events by influencing platelet
activation and aggregation, potentially exacerbating vaso-
occlusive crises, one of the hallmark complications of SCA
[24]. While erythrocyte abnormalities remain central to SCA,
the emerging significance of eosinophils in inflammation,
immune modulation, endothelial dysfunction, and vaso-
occlusive events underscores their multifaceted role in
shaping the disease’s clinical manifestations and severity.
Further investigations into eosinophil-related mechanisms
hold promise for developing novel therapeutic strategies to
improve outcomes for individuals affected by SCA.
Inflammation and Immune Modulation
In Sickle Cell Anemia (SCA), the interplay between
inflammation and immune responses significantly contributes
to disease pathogenesis and severity. Eosinophils, a subset of
white blood cells, are increasingly recognized for their dual
role in propagating inflammation and modulating immune
responses, thereby influencing the clinical course of SCA
[25-30]. Eosinophils actively participate in the inflammatory
cascade by releasing a spectrum of pro-inflammatory
mediators such as leukotrienes, cytokines (IL-4, IL-13),
and granule proteins (MBP-1, ECP). These molecules are
implicated in enhancing inflammation, exacerbating tissue
injury, and potentially intensifying the vaso-occlusive
events characteristic of SCA [31]. Eosinophils possess the
ability to modulate immune responses by influencing the
activity of T-cells and other immune cells. They contribute to
immune dysregulation observed in SCA, altering the immune
landscape and exacerbating the inflammatory milieu within
the affected tissues and vasculature [32]. While known for
their pro-inflammatory functions, eosinophils also exhibit
anti-inflammatory properties. They can contribute to the
resolution of inflammation by promoting the clearance of
cellular debris and participating in tissue repair processes.
However, in the context of SCA, dysregulated eosinophilic
responses may tip the balance towards sustained
Copyright© Obeagu EI.
 3
inflammation, perpetuating tissue damage and disease
progression [31].
Eosinophils’ interactions with endothelial cells play a
pivotal role in endothelial activation. This interaction triggers
the expression of adhesion molecules and induces oxidative
stress, contributing to endothelial dysfunction observed in
SCA. The resultant endothelial activation further amplifies
the inflammatory responses, promoting vaso-occlusive
events and tissue ischemia [33-36]. Eosinophils influence the
cytokine milieu within the inflammatory microenvironment.
Their secretion of specific cytokines contributes to the
complex cytokine network in SCA, affecting the balance
between pro-inflammatory and anti-inflammatory signals,
consequently influencing disease severity. Eosinophils,
through their involvement in modulating inflammatory
responses and immune dysregulation, significantly impact
the pathogenesis and progression of Sickle Cell Anemia.
Further exploration into the specific mechanisms by which
eosinophils contribute to inflammation and immune
modulation in SCA is essential for developing targeted
therapies to mitigate the inflammatory burden and improve
clinical outcomes for individuals affected by this challenging
hematological disorder.
Vascular Dysfunction and Endothelial
Interactions
The pathophysiology of Sickle Cell Anemia (SCA)
extends beyond erythrocyte abnormalities, encompassing
vascular dysfunction and endothelial interactions.
Eosinophils, a subset of white blood cells, are implicated in
promoting endothelial dysfunction, thereby exacerbating
vascular complications observed in SCA [36-40]. Eosinophils
contribute to endothelial activation by inducing oxidative
stress and promoting the expression of adhesion molecules
on endothelial surfaces. This endothelial activation, observed
in SCA, enhances the adhesive properties of endothelial
cells, facilitating the adherence of sickle cells and other
blood components, consequently contributing to vaso-
occlusive events [41]. The interaction between eosinophils
and endothelial cells leads to the generation of oxidative
stress within the vascular microenvironment. This oxidative
stress, coupled with inflammatory mediators released by
eosinophils, further amplifies endothelial dysfunction,
exacerbating tissue damage and promoting vaso-occlusive
crises in SCA [23].
Eosinophils’ involvement in inducing endothelial
dysfunction and enhancing adhesion molecule expression
contributes significantly to the pathogenesis of vaso-occlusive
events in SCA. These events, characterized by the occlusion
of blood vessels by sickled red blood cells, further propagate
tissue ischemia and organ damage, hallmark features of
Obeagu EI. Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity.
Haematol Int J 2024, 8(1): 00223.
Haematology International Journal
SCA complications [23]. Eosinophils are implicated in
promoting thrombotic events through interactions with
platelets and their ability to activate coagulation pathways.
In SCA, dysregulated eosinophil-platelet interactions may
contribute to the pro-thrombotic milieu, exacerbating the
propensity for thrombotic complications [42]. Eosinophils
may impact vascular tone and blood flow regulation by
contributing to endothelial dysfunction. This influence on
vascular physiology can further compound the vascular
complications seen in SCA, contributing to tissue ischemia
and end-organ damage. Eosinophils, through their
interactions with endothelial cells and their contributions
to endothelial dysfunction, significantly impact vascular
complications in Sickle Cell Anemia. Further elucidation of
the molecular mechanisms governing eosinophil-endothelial
interactions in SCA is crucial for the development of targeted
interventions aimed at preserving vascular function and
mitigating the detrimental consequences of vascular
dysfunction in individuals affected by this challenging
hematologic disorder.
Therapeutic Implications and Future
Directions
The emerging understanding of eosinophils’ multifaceted
involvement in SCA pathophysiology has opened avenues
for potential therapeutic interventions aimed at mitigating
disease severity. Exploring strategies targeting eosinophil-
related pathways presents promising prospects for
improving clinical outcomes and managing complications
associated with SCA. Developing therapies specifically
targeting eosinophils holds potential in attenuating their
deleterious effects in SCA. Eosinophil-lowering agents or
inhibitors targeting eosinophil activation and recruitment
pathways could help alleviate inflammatory burden and
mitigate tissue damage associated with eosinophilic
responses. Given the significant contribution of eosinophils
to the inflammatory milieu in SCA, anti-inflammatory
agents targeting pathways influenced by eosinophil-derived
mediators (leukotrienes, cytokines) could help dampen
the excessive inflammatory response, thereby reducing
tissue injury and vaso-occlusive events. Adopting precision
medicine strategies to identify individuals with heightened
eosinophil-mediated complications might aid in tailoring
therapeutic interventions. This personalized approach could
involve identifying biomarkers or genetic profiles indicative
of increased eosinophil activity to guide targeted therapies
for specific patient subsets.
Therapeutic strategies focused on preserving endothelial
function and mitigating endothelial activation induced by
eosinophils could prove beneficial. Agents targeting oxidative
stress, adhesion molecule expression, and endothelial repair
mechanisms might help improve vascular health and reduce
Copyright© Obeagu EI.
 4
vaso-occlusive events in SCA. Continued research into the
specific molecular pathways governing eosinophil-mediated
effects in SCA is essential. Identifying novel therapeutic
targets, such as signaling pathways involved in eosinophil-
endothelial interactions or immune modulation, could lead
to the development of innovative therapies for managing
SCA complications. Conducting well-designed clinical
trials focusing on eosinophil-targeted therapies or anti-
inflammatory interventions in SCA is crucial for translating
preclinical findings into effective treatments. Collaborative
efforts between basic research and clinical trials are
imperative to evaluate the safety and efficacy of potential
therapies. Enhancing patient care by integrating novel
therapeutic approaches into comprehensive management
strategies is pivotal. Holistic care that encompasses
traditional disease-modifying therapies alongside emerging
eosinophil-targeted interventions could significantly
improve the quality of life for individuals living with SCA.
Conclusion
The intricate interplay between eosinophils and Sickle
Cell Anemia (SCA) pathophysiology has unveiled a new
dimension in understanding the disease’s complexity
beyond erythrocyte abnormalities. Eosinophils, traditionally
recognized for their roles in allergic responses and immune
defense, have emerged as significant contributors to
inflammation, immune dysregulation, vascular dysfunction,
and disease severity in SCA. Therapeutically targeting
eosinophil-related pathways presents a promising approach
to attenuate the inflammatory burden, mitigate endothelial
dysfunction, and improve clinical outcomes in individuals
affected by SCA. Strategies such as eosinophil-lowering
agents, anti-inflammatory therapies, precision medicine
approaches, and endothelial protection strategies offer
potential avenues for intervention.
Understanding the intricate interactions between
eosinophils and SCA pathophysiology is critical for
unraveling novel therapeutic targets and enhancing patient
care. Advancements in eosinophil-related research hold
promise in revolutionizing the management of Sickle Cell
Anemia, paving the way for tailored interventions that
alleviate disease severity and improve the quality of life for
individuals living with this challenging hematologic disorder.
References
1. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO
(2015) Sickle cell anaemia: a review. Sch J App Med Sci
3(6B): 2244-2252.
2. Obeagu EI (2020) Erythropoeitin in Sickle Cell Anaemia:
A Review. IJRSMHS 5(2): 22-28.
Obeagu EI. Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity.
Haematol Int J 2024, 8(1): 00223.
Haematology International Journal
3. Obeagu EI (2018) Sickle Cell Anaemia: Haemolysis and
Anemia. Int J Curr Res Chem Pharm Sci 5(10): 20-21.
4. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe
OS, Nakyeyune S, et al. (2022) An Update on Interferon
Gamma and C Reactive Proteins in Sickle Cell Anaemia
Crisis. J Biomed Sci 11(10): 84.
5. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB (2023)
Antioxidants in the management of sickle cell anaemia:
an area to be exploited for the wellbeing of the patients.
International Research in Medical and Health Sciences
6(4): 12-17.
6. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell
anaemia: a gestational enigma. (2023) European Journal
of Biomedical and Pharmaceutical Sciences 10((9): 72-
75
7. Obeagu EI (2018) An update on micro RNA in sickle cell
disease. Int J Adv Res Biol Sci 5: 157-158.
8. Obeagu EI, Babar Q (2021) Covid-19 and Sickle Cell
Anemia: Susceptibility and Severity. J Clinical and
Laboratory Research 4(1): 56
9. Tolksdorf C, Moritz E, Wolf R, Meyer U, Marx S, et al.
(2023) Platelet-derived s1p and its relevance for the
communication with immune cells in multiple human
diseases. Int J Mol Sci 23(18): 10278.
10. Mantovani A, Dinarello CA, Molgora M, Garlanda C (2019)
Interleukin-1 and related cytokines in the regulation of
inflammation and immunity. Immunity 50(4): 778-795.
11. Obeagu EI (2023) Depression in Sickle Cell Anemia:
An Overlooked Battle. Int J Curr Res Chem Pharm Sci
10(10): 41-44.
12. Obeagu EI, Obeagu GU (2023) Evaluation of
Hematological Parameters of Sickle Cell Anemia Patients
with Osteomyelitis in A Tertiary Hospital in Enugu,
Nigeria. Journal of Clinical and Laboratory Research
6(1): 94.
13. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU et
al. (2023) Hyperthyroidism in sickle cell anaemia. Int J
Adv Res Biol Sci 10(3): 81-89.
14. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC (2023)
Nosocomial infections in sickle cell anemia patients:
Prevention through multi-disciplinary approach: A
review. Medicine 102(48): e36462.
15. Njar VE, Ogunnaya FU, Obeagu EI (2023) Knowledge and
Prevalence of the Sickle Cell Trait among Undergraduate
Students of the University of Calabar. Prevalence 5(100):
Copyright© Obeagu EI.
 5
5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B (2018)
Expression of micro RNA 144 in sickle cell disease. Int J
Curr Res Med Sc 4(3): 26-32.
17. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU
(2023) Anaemia in children under five years: African
perspectives. Int J Curr Res Biol Med 1: 1-7.
18. Pallis FR, Conran N, Fertrin KY, Saad STO, Costa FF, et al.
(2014) Hydroxycarbamide reduces eosinophil adhesion
and degranulation in sickle cell anaemia patients. British
Journal of Haematology 164(2): 286-295.
19. Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott
A, et al. (2020) Blood eosinophil count in the general
population: typical values and potential confounders.
Eur Respir J 55(5): 1901874
20. Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson
DJ, et al. (2021) Eosinophils in health and disease: a
state-of-the-art review. Mayo Clin Proc 96 (10): 2694-
2707.
21. Zhen Y, Shu W, Hou X, Wang Y (2021) Innate immune
system orchestrates metabolic homeostasis and
dysfunction in visceral adipose tissue during obesity.
Frontiers in Immunology 12: 702835.
22. Simoes FC, Riley PR (2022) Immune cells in cardiac
repair and regeneration. Development 149(8): 199906.
23. Cook JMM, Marchese ME, Abdala VH (2011) Vascular cell
adhesion molecule-1 expression and signaling during
disease: regulation by reactive oxygen species and
antioxidants. Antioxidants Redox Signal 15(6): 1607-
1638.
24. Azevedo DJT, Malmegrim KC (2020) Immune
mechanisms involved in sickle cell disease pathogenesis:
current knowledge and perspectives. Immunol Lett 224:
1-11.
25. Obeagu EI (2018) Sickle cell anaemia: Historical
perspective, Pathophysiology and Clinical manifestations.
Int J Curr Res Chem Pharm Sci 5(11): 13-15.
26. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in
Pregnancy: A Review. International Research in Medical
and Health Sciences 6(2): 10-13.
27. Obeagu EI, Mohamod AH. An update on Iron deficiency
anaemia among children with congenital heart disease.
Int J Curr Res Chem Pharm Sci 10(4): 45-48.
28. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022)
Obeagu EI. Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity.
Haematol Int J 2024, 8(1): 00223.
Haematology International Journal
Evaluationof Trace Elements in Sickle Cell Anaemia
Patients Attending Imo State Specialist Hospital, Owerri.
Madonna University Journal of Medicine and Health
Sciences 2(1): 218-234.
29. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, et al.
(2023) Assessment Of Factors Precipitating Sickle Cell
Crises Among Under 5-Years Children Attending Sickle
Cell Clinic Of Murtala Muhammad Specialist Hospital,
Kano. Blood 11:16.
30. Obeagu EI (2018) Vaso-occlusion and adhesion
molecules in sickle cells disease. Int J Curr Res Med Sci
4(11): 33-35.
31. Vatrella A, Maglio A, Pelaia C, Ciampo L, Pelaia G, et
al. (2022) Eosinophilic inflammation: An appealing
target for pharmacologic treatments in severe asthma.
Biomedicines 10(9): 2181.
32. Spencer LA, Weller PF (2010) Eosinophils and Th2
immunity: contemporary insights. Immunol Cell Boil
88(3): 250-256.
33. Aloh GS, Obeagu, EI, Okoroiwu IL, Odo, C, Ugwu GU et
al. (2015) Antioxidant-Mediated Heinz Bodies Levels of
Sickle Erythrocytes under Drug-Induced Oxidative Stress.
European Journal of Biomedical and Pharmaceutical
Sciences 2(1): 502-507.
34. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV
resistance in patients with Sickle Cell Anaemia. NIJSES
3(2): 56-59.
35. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO
(2023) Sickle Cell Anaemia: Current Burden in Africa.
International Journal of Innovative and Applied Research
11(2): 12-14.
36. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN
(2014) Haematological parameters among sickle cell
anemia patients’ state and haemoglobin genotype AA
individuals at Michael Okpara University of Agriculture,
Umudike, Abia State, Nigeria. Int J Curr Microbiol App Sci
3(3): 1000-1005.
37. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU
(2023) Obsterics characteristics that effect the newborn
outcomes. Int J Adv Res Biol Sci 10(3): 134-143.
38. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of
nutritional anaemia in Africa: A Review. Int J Adv Res
Biol Sci 10(2): 160-163.
39. Ifeanyi E (2015) Erythropoietin (Epo) Level in Sickle Cell
Anaemia (HbSS) With Falciparum Malaria Infection in
University Health Services, Michael Okpara University of
Copyright© Obeagu EI.
 6
Agriculture, Umudike, Abia State, Nigeria. Paripex Indian
Journal Of Research 4(6): 258-259
40. Ifeanyi OE, Stanley MC, Nwakaego OB (2014) Comparative
analysis of some haematological parameters in sickle
cell patients in steady and crisis state at Michael Okpara
University of agriculture, Umudike, Abia state, Nigeria.
Int J Curr Microbiol App Sci 3(3): 1046-1050.
41. Ifeanyi EO, Uzoma GO (2020) Malaria and The Sickle
Cell Trait: Conferring Selective Protective Advantage to
Malaria. J Clin Med Res 2: 1-4.
Obeagu EI. Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity.
Haematol Int J 2024, 8(1): 00223.
Haematology International Journal
42. Zetter B (2023) The ability for cells to harness alternative
splicing enables them to diversify their proteome in
order to carry out complex biological functions and
adapt to external and internal stimuli. The spliceosome
is the multiprotein-RNA complex charged with the
intricate task of alternative splicing. Aberrant splicing
can arise from abnormal spliceosomes or splicing
factors and drive cancer development and progression.
This review will provide an. Reviews in Molecular and
Cellular Oncology pp: 44.
Copyright© Obeagu EI.